Avidity Biosciences, Inc. (RNAM)
Price History
Feb 27, 2026 — Mar 8, 2026Investment Snapshot
- P/B of 6.69 — trading above book value
- Piotroski F-Score 1/9 — signs of financial weakness
- Loss-making — negative ROE of -31.3%
- Revenue growing at 72% annually
Avidity Biosciences, Inc. (RNAM) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $11.3 billion . Key value metrics: P/B ratio 6.69, Piotroski F-Score 1 out of 9 .
Value Score
Key Metrics
Avidity Biosciences, Inc. — Fundamental Analysis Summary
On financial health, RNAM shows a weak Piotroski F-Score of 1/9, a signal of deteriorating financial health, and negative return on equity of -31.3%, and minimal leverage with a debt-to-equity ratio of 0.16.
StockPik's composite Value Score for RNAM is 20/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
RNAM shows revenue growing at 72% year-over-year, with earnings declining at 112%.